Despite the clear net clinical benefit of oral anticoagulation (OAC) in atrial fibrillation (AF)
patients at risk for stroke, major bleeding events (especially intra-cranial bleeds) may be …

Background—Many patients receiving cardiac rhythm devices have conditions requiring
antiplatelet (AP) and/or anticoagulant (AC) therapy. Current guidelines recommend a …

Since the advent of the non-vitamin K antagonist oral anticoagulant (NOAC) agents, which
act as direct thrombin inhibitors or inhibitors of Factor Xa, clinicians are provided with …

Aims The infection rates of implantable cardioverter-defibrillators systems (ICDs) are higher
than that of permanent pacemaker. Risk factors associated with ICD infection have not been …

BACKGROUND: Management of oral anticoagulation in patients undergoing pacemaker
(PPM) or implantable cardioverter-defibrillator (ICD) implantation remains controversial …

Aims Pocket haematoma is a common complication following pacemaker implantation.
Impact of this complication on post-procedural outcomes has previously not been …

Background: Switching warfarin for heparin has been a practice for managing
periprocedural anticoagulation in high‐risk patients undergoing device‐related procedures …

Chronic kidney disease patients appear to be predisposed to heart rhythm disorders,
including atrial fibrillation/atrial flutter, ventricular arrhythmias, and supraventricular …

METHODS: All relevant studies identified in MEDLINE/PubMed, The Cochrane
Collaboration CENTRAL, clinicaltrials. org and in bibliographies of key articles. Estimates …

The growing implantations of electrophysiological devices in the context of increasing rates
of chronic antithrombotic therapy in cardiovascular disease patients underscore the …